A Phase Ib, Dose Escalation, Multiple Dose Trial With HuMax-IL8 in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2016
At a glance
- Drugs HuMax IL8 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; Cormorant Pharmaceuticals
- 05 Dec 2016 Status changed from active, no longer recruiting to completed.
- 02 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2017.